Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03978767 · ClinicalTrials.gov registry record · Phase 2
Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 287
- Enrollment target
NCT03978767: Completed Phase 2 study, sponsored by Washington University School of Medicine.
NCT03978767 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 287 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (116% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03978767, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 287 participants
- Enrollment target
Study Summary
A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.
Primary Outcome
measurement of anti-hypertensive requirements at time of discharge
Interventions
- DRUG Ibuprofen 600 mg
- DRUG Acetaminophen
- DRUG Ketorolac
- DRUG Oxycodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
What the finished NCT03978767 record still lists
NCT03978767 is an interventional study that assigns participants to a tested intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (116% higher).
The record links to 0 conditions, and to 4 interventions - of which Ibuprofen 600 mg is the first listed.
NCT03978767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03978767 about?
NCT03978767 is a clinical study titled "Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial". A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.
What is the current status of trial NCT03978767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 287 participants. The study started on 2019-06-10. Estimated completion is 2026-06-15.
What interventions are being tested in trial NCT03978767?
The interventions under investigation include: Ibuprofen 600 mg (DRUG), Acetaminophen (DRUG), Ketorolac (DRUG), Oxycodone (DRUG).
Who is sponsoring clinical trial NCT03978767?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03978767's enrollment target sits among peer trials
287 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI